医学
重症监护医学
疾病
免疫疗法
甲状腺
免疫系统
靶向治疗
甲状腺炎
自身免疫性疾病
治疗方法
甲状腺切除术
生物信息学
免疫学
评论文章
自身免疫
甲状腺激素
甲状腺疾病
医疗
药物治疗
精密医学
抗甲状腺药物
格雷夫斯病
作者
Alessandro Antonelli,Poupak Fallahi
标识
DOI:10.2174/0113816128537581261007065942
摘要
Graves' Disease (GD) is the leading cause of autoimmune hyperthyroidism and is still considered a challenging clinical condition. Antithyroid drugs, radioactive iodine, and thyroidectomy have long been used as main treatments. These approaches are generally effective in restoring euthyroidism and controlling thyroid function, even if they cannot target the underlying autoimmune mechanisms implicated in the disease. As a result, relapses after medical therapy remain frequent, whereas definitive treatments often lead to permanent hypothyroidism and the need for a lifelong thyroid hormone replacement. New results in the study of immunological mechanisms underlying GD have led to the development of targeted therapies. Targeted strategies are based on key components of disease pathogenesis, such as the thyrotropin receptor, B lymphocytes, co-stimulatory immune pathways, the insulin-like growth factor-1 receptor, and neonatal Fc receptors. A pivotal step in the development of targeted mechanism-based therapies for GD has been reached with the approval of teprotumumab. Several targeted therapies have been evaluated, such as K1-70, iscalimab, rituximab, tocilizumab, batoclimab, and the antigen-specific immunotherapy ATX-GD-59. This review highlights the limitations of currently available treatment options by examining the most promising emerging therapies and the future horizons for precision medicine in GD. Advances in the therapeutic landscape offer disease-modifying strategies that could complement and potentially replace current treatment strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI